ClinicalTrials.gg
Sign In
CompletedNCT01163877Updated Oct 14, 2013

Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma

An interventional study of Fe-57 orally, Fe-58 intravenously in Malaria, Falciparum, Hookworm Infections and Schistosoma Haematobium, sponsored by Swiss Federal Institute of Technology. Completed at 1 site in Côte D'Ivoire. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-10-14.

Sponsored by Swiss Federal Institute of Technology · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
12 Years to 16 Years
Sex
All
01

Study summary

The aim of this study is to investigate the change in iron metabolism in relation to malaria and helminth infections using a stable isotope technique.

Read the detailed description

The aim of the study is to determine how iron metabolism in subjects with infectious diseases (malaria, hookworm or S. haematobium) differs while infected and after treatment, i.e. the same individuals will be restudied while free of infection.

02

Conditions studied

  • Malaria, Falciparum
  • Hookworm Infections
  • Schistosoma Haematobium

Keywords

  • iron absorption
  • iron utilization
  • malaria
  • helminth
  • Ivory Coast
  • Acute symptomatic uncomplicated falciparum malaria
  • Asymptomatic falciparum malaria
  • Moderate to heavy hookworm infection
  • Heavy Schistosoma haematobium infection
03

In context

Malaria, Falciparum

455 studies on the registry are indexed under Malaria, Falciparum; 37 are open to participants now.

This study's enrollment of 43 is below the median of 126 across 376 interventional studies indexed under Malaria, Falciparum.

Browse Malaria, Falciparum studies →

Lead sponsor

Swiss Federal Institute of Technology is the lead sponsor of 154 studies on the registry; 10 are open to participants now.

Browse Swiss Federal Institute of Technology studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged 12 to 16 years
  • Body weight > 30 kg
  • no chronic medical illnesses
  • no intake of vitamin/mineral supplements 2 weeks before the study and until the last blood drawing
  • For each of the 4 arms the respective disease needs to be present (symptomatic malaria, asymptomatic malaria, hookworm infection, S. haematobium infection) without any other concurrent infection

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Other
    Symptomatic malaria infection

    Dietary Supplement: Fe-57 orally, Fe-58 intravenously

  • Other
    Asymptomatic malaria infection

    Dietary Supplement: Fe-57 orally, Fe-58 intravenously

  • Other
    Hookworm infection

    Dietary Supplement: Fe-57 orally, Fe-58 intravenously

  • Other
    Schistosoma haematobium infection

    Dietary Supplement: Fe-57 orally, Fe-58 intravenously

Interventions

  • Dietary supplementFe-57 orally, Fe-58 intravenously

    Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.

06

What researchers measure

Primary outcomes

  1. Isotope absorption into blood stream

    Time frame: Day 15

  2. Isotope absorption into blood stream

    Time frame: Day 43

Secondary outcomes

  1. Isotope incorporation into erythrocytes

    Time frame: Day 15

  2. Biochemical parameters of iron status and infection

    Time frame: Day 1

  3. Biochemical parameters of iron status and infection

    Time frame: Day 15

  4. Biochemical parameters of iron status and infection

    Time frame: Day 29

  5. Biochemical parameters of iron status and infection

    Time frame: Day 43

  6. Isotope incorporation into erythrocytes

    Time frame: Day 43

07

Study locations

1 site
  • Taabo Cité Hospital
    Taabo, Côte D'Ivoire
08

References and documents

Publications

  • Rohner F, Zimmermann MB, Amon RJ, Vounatsou P, Tschannen AB, N'goran EK, Nindjin C, Cacou MC, Te-Bonle MD, Aka H, Sess DE, Utzinger J, Hurrell RF. In a randomized controlled trial of iron fortification, anthelmintic treatment, and intermittent preventive treatment of malaria for anemia control in Ivorian children, only anthelmintic treatment shows modest benefit. J Nutr. 2010 Mar;140(3):635-41. doi: 10.3945/jn.109.114256. Epub 2010 Jan 27. PubMed 20107144 ↗
  • Wegmuller R, Camara F, Zimmermann MB, Adou P, Hurrell RF. Salt dual-fortified with iodine and micronized ground ferric pyrophosphate affects iron status but not hemoglobin in children in Cote d'Ivoire. J Nutr. 2006 Jul;136(7):1814-20. doi: 10.1093/jn/136.7.1814. PubMed 16772442 ↗
  • Kastenmayer P, Davidsson L, Galan P, Cherouvrier F, Hercberg S, Hurrell RF. A double stable isotope technique for measuring iron absorption in infants. Br J Nutr. 1994 Mar;71(3):411-24. doi: 10.1079/bjn19940148. PubMed 8172870 ↗
  • Walczyk T, Davidsson L, Zavaleta N, Hurrell RF. Stable isotope labels as a tool to determine the iron absorption by Peruvian school children from a breakfast meal. Fresenius Journal of Analytical Chemistry 359: 445-449, 1997.
  • Glinz D, Hurrell RF, Righetti AA, Zeder C, Adiossan LG, Tjalsma H, Utzinger J, Zimmermann MB, N'Goran EK, Wegmuller R. In Ivorian school-age children, infection with hookworm does not reduce dietary iron absorption or systemic iron utilization, whereas afebrile Plasmodium falciparum infection reduces iron absorption by half. Am J Clin Nutr. 2015 Mar;101(3):462-70. doi: 10.3945/ajcn.114.090175. Epub 2015 Feb 4. PubMed 25733630 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01163877
Lead sponsor
Swiss Federal Institute of Technology
Responsible party
Prof. Michael B. Zimmermann (Prof, Swiss Federal Institute of Technology) — Principal investigator
First posted
Jul 16, 2010
Start date
Apr 2010
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Oct 14, 2013

Study contacts

Rita Wegmüller, Dr.
principal investigator · Swiss Federal Institute of Technology (ETH) Zurich

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Malaria, Falciparum →

Other studies from this sponsor

Swiss Federal Institute of Technology →

Start the discussion